Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5093210
Max Phase: Preclinical
Molecular Formula: C18H16ClN3OS
Molecular Weight: 357.87
Molecule Type: Unknown
Associated Items:
ID: ALA5093210
Max Phase: Preclinical
Molecular Formula: C18H16ClN3OS
Molecular Weight: 357.87
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1ccc(NC(=O)CSc2nccn2-c2ccc(Cl)cc2)cc1
Standard InChI: InChI=1S/C18H16ClN3OS/c1-13-2-6-15(7-3-13)21-17(23)12-24-18-20-10-11-22(18)16-8-4-14(19)5-9-16/h2-11H,12H2,1H3,(H,21,23)
Standard InChI Key: QJQVMJSGMOLKBL-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 357.87 | Molecular Weight (Monoisotopic): 357.0703 | AlogP: 4.56 | #Rotatable Bonds: 5 |
Polar Surface Area: 46.92 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 13.92 | CX Basic pKa: 4.48 | CX LogP: 4.77 | CX LogD: 4.77 |
Aromatic Rings: 3 | Heavy Atoms: 24 | QED Weighted: 0.68 | Np Likeness Score: -2.62 |
1. (2021) Slc26a3 inhibitors and use thereof, |
Source(1):